| Year |
Citation |
Score |
| 2021 |
Singleton DC, Mowday AM, Guise CP, Syddall SP, Bai SY, Li D, Ashoorzadeh A, Smaill JB, Wilson WR, Patterson AV. Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411 leading to therapeutic benefit. Cancer Gene Therapy. PMID 34837065 DOI: 10.1038/s41417-021-00409-2 |
0.584 |
|
| 2019 |
Liew LP, Singleton DC, Wong WW, Cheng GJ, Jamieson SMF, Hay M. Hypoxia Activated Prodrugs of PERK Inhibitors. Chemistry, An Asian Journal. PMID 30615821 DOI: 10.1002/asia.201801826 |
0.301 |
|
| 2016 |
McIntyre A, Hulikova A, Ledaki I, Snell C, Singleton D, Steers G, Seden P, Jones D, Bridges E, Wigfield S, Li JL, Russell A, Swietach P, Harris AL. Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research. PMID 27197160 DOI: 10.1158/0008-5472.Can-15-1862 |
0.588 |
|
| 2014 |
Singleton DC, Rouhi P, Zois CE, Haider S, Li JL, Kessler BM, Cao Y, Harris AL. Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene. PMID 25486436 DOI: 10.1038/onc.2014.396 |
0.707 |
|
| 2014 |
Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, ... ... Singleton DC, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry. 1-33. PMID 25347767 DOI: 10.3109/14756366.2014.966704 |
0.596 |
|
| 2013 |
Singleton DC, Harris AL. Microenvironmental induced essentiality of autophagy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2791-3. PMID 23613319 DOI: 10.1158/1078-0432.CCR-13-0634 |
0.539 |
|
| 2013 |
Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, Buffa F, Huffman M, Sinn AL, Silver J, Turley H, Leek R, Harris AL, Ivan M. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine (Berlin, Germany). 91: 749-58. PMID 23361368 DOI: 10.1007/s00109-013-0996-2 |
0.623 |
|
| 2013 |
Pike LR, Singleton DC, Buffa F, Abramczyk O, Phadwal K, Li JL, Simon AK, Murray JT, Harris AL. Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. The Biochemical Journal. 449: 389-400. PMID 23078367 DOI: 10.1042/Bj20120972 |
0.739 |
|
| 2012 |
Singleton DC, Harris AL. Targeting the ATF4 pathway in cancer therapy. Expert Opinion On Therapeutic Targets. 16: 1189-202. PMID 23009153 DOI: 10.1517/14728222.2012.728207 |
0.496 |
|
| 2009 |
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules (Basel, Switzerland). 14: 4517-45. PMID 19924084 DOI: 10.3390/molecules14114517 |
0.581 |
|
| 2009 |
Rzymski T, Milani M, Singleton DC, Harris AL. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle (Georgetown, Tex.). 8: 3838-47. PMID 19887912 DOI: 10.4161/cc.8.23.10086 |
0.736 |
|
| 2007 |
Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer Gene Therapy. 14: 953-67. PMID 17975564 DOI: 10.1038/sj.cgt.7701088 |
0.345 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2024 |
Lee TW, Singleton DC, Harms JK, Lu M, McManaway SP, Lai A, Tercel M, Pruijn FB, Macann AMJ, Hunter FW, Wilson WR, Jamieson SMF. Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models. Molecular Oncology. PMID 38426642 DOI: 10.1002/1878-0261.13620 |
0.291 |
|
| 2018 |
Leung EY, Askarian-Amiri ME, Singleton DC, Ferraro-Peyret C, Joseph WR, Finlay GJ, Broom RJ, Kakadia PM, Bohlander SK, Marshall E, Baguley BC. Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations. Frontiers in Oncology. 8: 425. PMID 30370249 DOI: 10.3389/fonc.2018.00425 |
0.288 |
|
| 2020 |
Singleton DC, Dechaume AL, Murray PM, Katt WP, Baguley BC, Leung EY. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. Bmc Cancer. 20: 470. PMID 32450839 DOI: 10.1186/S12885-020-06885-3 |
0.282 |
|
| 2022 |
Cheng GJ, Leung EY, Singleton DC. breast cancer models for studying mechanisms of resistance to endocrine therapy. Exploration of Targeted Anti-Tumor Therapy. 3: 297-320. PMID 36045910 DOI: 10.37349/etat.2022.00084 |
0.269 |
|
| 2020 |
Hearn JI, Green TN, Chopra M, Nursalim YNS, Ladvanszky L, Knowlton N, Blenkiron C, Poulsen RC, Singleton DC, Bohlander SK, Kalev-Zylinska ML. N-Methyl-D-Aspartate Receptor Hypofunction in Meg-01 Cells Reveals a Role for Intracellular Calcium Homeostasis in Balancing Megakaryocytic-Erythroid Differentiation. Thrombosis and Haemostasis. 120: 671-686. PMID 32289863 DOI: 10.1055/s-0040-1708483 |
0.243 |
|
| 2020 |
Lee TW, Lai A, Harms JK, Singleton DC, Dickson BD, Macann AMJ, Hay MP, Jamieson SMF. Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. Cancers. 12. PMID 33322840 DOI: 10.3390/cancers12123743 |
0.232 |
|
| 2021 |
Singleton DC, Macann A, Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. Nature Reviews. Clinical Oncology. PMID 34326502 DOI: 10.1038/s41571-021-00539-4 |
0.213 |
|
| 2008 |
Singleton D, Syddall S, Bai S, Li D, Denny W, Wilson W, Patterson A. 300 POSTER Oncolytic adenovirus ONYX-411NTR enhances the antitumour efficacy of the bioreductive alkylator prodrug PR-104 European Journal of Cancer Supplements. 6: 96. DOI: 10.1016/S1359-6349(08)72234-1 |
0.136 |
|
| 2015 |
Clark PG, Vieira LC, Tallant C, Fedorov O, Singleton DC, Rogers CM, Monteiro OP, Bennett JM, Baronio R, Müller S, Daniels DL, Méndez J, Knapp S, Brennan PE, Dixon DJ. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angewandte Chemie (Weinheim An Der Bergstrasse, Germany). 127: 6315-6319. PMID 27346896 DOI: 10.1002/ange.201501394 |
0.11 |
|
| 2015 |
Clark PG, Vieira LC, Tallant C, Fedorov O, Singleton DC, Rogers CM, Monteiro OP, Bennett JM, Baronio R, Müller S, Daniels DL, Méndez J, Knapp S, Brennan PE, Dixon DJ. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angewandte Chemie (International Ed. in English). 54: 6217-21. PMID 25864491 DOI: 10.1002/Anie.201501394 |
0.11 |
|
| 2020 |
Lee T, Yong H, Bhatta S, Singleton D, Lipert B, Tsai P, Bohlander S, Print C, Hunter F, Wilson W, Jamieson S. Functional genomics screens to identify genes involved in tolerance of tumour microenvironment stress European Journal of Cancer. 138: S30. DOI: 10.1016/s0959-8049(20)31147-3 |
0.109 |
|
| 2014 |
Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C, Picaud S, Philpott M, Monteiro OP, Rogers CM, Conway SJ, Rooney TP, Tumber A, Yapp C, Filippakopoulos P, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. Journal of the American Chemical Society. 136: 9308-19. PMID 24946055 DOI: 10.1021/Ja412434F |
0.092 |
|
| Hide low-probability matches. |